Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Vivos Therapeutics (VVOS) Equity Average (2020 - 2025)

Vivos Therapeutics' Equity Average history spans 6 years, with the latest figure at $521000.0 for Q4 2025.

  • Quarterly results put Equity Average at $521000.0 for Q4 2025, down 93.33% from a year ago — trailing twelve months through Dec 2025 was $521000.0 (down 93.33% YoY), and the annual figure for FY2025 was $3.2 million, down 22.73%.
  • Equity Average for Q4 2025 was $521000.0 at Vivos Therapeutics, down from $3.6 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $34.5 million in Q3 2021 to a low of $228500.0 in Q4 2023.
  • The 5-year median for Equity Average is $6.6 million (2024), against an average of $10.5 million.
  • The sharpest move saw Equity Average crashed 96.88% in 2023, then soared 3317.72% in 2024.
  • Year by year, Equity Average stood at $29.0 million in 2021, then plummeted by 74.73% to $7.3 million in 2022, then crashed by 96.88% to $228500.0 in 2023, then soared by 3317.72% to $7.8 million in 2024, then tumbled by 93.33% to $521000.0 in 2025.
  • According to Business Quant data, Equity Average over the past three periods came in at $521000.0, $3.6 million, and $4.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.